Eli Lilly Agrees To Buy Morphic For $57 Per Share In Cash, An Aggregate Of Approximately $3.2B, Acquisition To Expand Lilly's Immunology Pipeline With Oral Integrin Therapies
Portfolio Pulse from Benzinga Newsdesk
Eli Lilly has agreed to acquire Morphic for $57 per share in cash, totaling approximately $3.2 billion. This acquisition aims to expand Lilly's immunology pipeline with oral integrin therapies.
July 08, 2024 | 10:49 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Eli Lilly's acquisition of Morphic for $3.2 billion is set to expand its immunology pipeline with oral integrin therapies, potentially enhancing its product offerings and market position.
The acquisition of Morphic will likely strengthen Eli Lilly's immunology pipeline, providing new therapeutic options and potentially increasing its market share in the immunology sector. This strategic move is expected to positively impact Eli Lilly's stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100
POSITIVE IMPACT
Morphic's acquisition by Eli Lilly for $57 per share in cash, totaling $3.2 billion, is a significant premium over its current market price, likely leading to a short-term increase in its stock price.
The acquisition price of $57 per share represents a significant premium over Morphic's current market price, which is likely to result in a short-term increase in its stock price as investors react to the news.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100